viewGlaxoSmithKline PLC

GlaxoSmithKline vows to produce 1bn vaccine adjuvant to support coronavirus candidates

The pharma giant is identifying potential vaccines that could be suitable to use the agent

GlaxoSmithKline PLC - GlaxoSmithKline vows to produce 1bn vaccine adjuvant to support Covid-19 candidates

GlaxoSmithKline PLC (LON:GSK) has vowed to produce 1bn doses of its pandemic vaccine adjuvant system to support the development of coronavirus (COVID19) treatment candidates.

Adjuvants are agents that improve the immune response of a vaccine and create a stronger immunity against infections.

READ: GlaxoSmithKline posts positive interim study on HIV prevention drug

The pharma giant, which will manufacture the doses next year, has confirmed several collaborations globally to identify COVID-19 candidates suitable to use the agent and is in discussion with more potential partners.

The profits generated from these deals will be reinvested in coronavirus-related research and long-term pandemic preparedness, either through GSK’s internal projects or with external partners.

Shares rose 1% to 1,671.08p on Thursday morning.

Quick facts: GlaxoSmithKline PLC

Price: 1575 GBX

Market: LSE
Market Cap: £79.02 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Inspired Energy raises up to £35mln in placing and open offer and fully...

Inspired Energy PLC's (LON:INSE) Mark Dickinson speaks to Proactive after announcing they've raised £35mln and struck a deal to acquire the 60% of Ignite Energy that it does not already own. Dickinson says the acquisition will accelerate the group's organic growth in optimisation services. In an...

11 hours, 25 minutes ago

2 min read